{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-197017","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.521624+00:00","generated_at":"2026-05-31T11:07:34.834968+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcellx Q2 net loss $27.2M; earns $68M milestone from Kite; IND cleared for myasthenia gravis","bullets":["Earned $68M milestone from Kite for iMMagine-1 enrollment in multiple myeloma.","Cash, equivalents, and marketable securities $646.8M as of June 30, 2024; funds operations into 2027.","Collaboration revenue $27.4M (up from $14.3M YoY); net loss $27.2M vs $23.9M YoY.","FDA cleared anito-cel IND for myasthenia gravis, a chronic autoimmune disease; wholly owned by Arcellx.","Kite initiated global Phase 3 iMMagine-3; abstract submitted for ASH Annual Meeting by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-197017","json":"https://secwatch.observer/filing/0001193125-24-197017.json","markdown":"https://secwatch.observer/filing/0001193125-24-197017.md","text":"https://secwatch.observer/filing/0001193125-24-197017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524197017/0001193125-24-197017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524197017/d874563d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:07:34.834968+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}